Grace Therapeutics Inc.
8 clinical trials · Sponsor
◉ Watch Grace Therapeutics Inc.
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH (NCT05995405) | Grace Therapeutics Inc. | 2023-10-20 |
| Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects (NCT05531890) | Grace Therapeutics Inc. | 2022-09-13 |
| Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects (NCT05517486) | Grace Therapeutics Inc. | 2022-07-26 |
| Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects (NCT05418348) | Grace Therapeutics Inc. | 2021-08-26 |
| A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) (NCT03361501) | Grace Therapeutics Inc. | 2018-02-01 |
| A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) (NCT03398005) | Grace Therapeutics Inc. | 2018-01-23 |
Track Grace Therapeutics Inc. automatically
Every clearance here is in the API, with alerts when new ones post.